Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Diabetes Care 30:370-371, 2007
DOI: 10.2337/dc06-2348
© 2007 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bowling, F. L.
Right arrow Articles by Boulton, A. J.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bowling, F. L.
Right arrow Articles by Boulton, A. J.M.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Emerging Treatments and Technologies
Brief Report

Larval Therapy: A Novel Treatment in Eliminating Methicillin-Resistant Staphylococcus aureus From Diabetic Foot Ulcers

Frank L. Bowling, BS, DPM1, Eleanna V. Salgami, MD, PHD1 and Andrew J.M. Boulton, MD, FRCP1,2

1 University Department of Medicine and Diabetes, Manchester Royal Infirmary, Manchester, U.K.
2 Division of Endocrinology, Metabolism, and Diabetes, University of Miami School of Medicine, Miami, Florida

Address correspondence and reprint requests to Frank L. Bowling, BS, DPM, c/o Prof. A.J.M. Boulton, University Department of Medicine and Diabetes, Manchester Royal Infirmary, Oxford Road, M13 9WL, Manchester, U.K. E-mail: frank.bowling@manchester.ac.uk

Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus • VPT, vibration perception threshold

The first 20% of the full text of this article appears below.


    INTRODUCTION
 
Overuse of antibiotics and the selection of broad- rather than narrow-spectrum agents have contributed to the high prevalence of methicillin-resistant Staphylococcus aureus (MRSA) colonization in diabetic foot wounds. Consequently, MRSA is now an endemic in both the community and hospital environments (1,2). We previously highlighted the problem (3) of MRSA colonization in our diabetic foot clinic (40% of S. aureus isolates were MRSA). A follow-up study (4) demonstrated that the number of foot wounds from which MRSA was isolated doubled in a 3-year period. Although terms such as critical colonization are not clearly defined, the risk of MRSA infection and bacteremia in patients with colonized ulcers is recognized (5,6). Furthermore, there is evidence (4) that MRSA colonization of chronic ulcers is associated with delayed healing times. Strategies to eliminate MRSA from colonized wounds are therefore essential and should include the use of simple, low-cost, effective treatments.

Larval therapy is suggested (7) to successfully remove sloughy necrotic tissue from ulcers and to facilitate healing. We hypothesized that larval therapy would eradicate MRSA colonization . . . [Full Text of this Article]


    RESEARCH DESIGN AND METHODS—
 

    RESULTS—
 

    CONCLUSIONS—
 

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
QJMHome page
M.P. Khanolkar, S.C. Bain, and J.W. Stephens
The diabetic foot
QJM, September 1, 2008; 101(9): 685 - 695.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
Z. T. Bloomgarden
The Diabetic Foot
Diabetes Care, February 1, 2008; 31(2): 372 - 376.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.